Breakthrough in Cancer Gene Therapy: Researchers Discover Promising Viral Protease mRNA

Researchers from the Beijing Institute of Pharmacology and Toxicology have made a significant discovery in the field of cancer gene therapy. According to their study, published in Nature Communications, lipid nanoparticles carrying mRNA encoding a viral 3 C protease can efficiently suppress tumors by selectively inducing tumor cell apoptosis. This breakthrough suggests that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic.

Key Takeaways:

The study used lipid nanoparticles to deliver mRNA encoding a viral 3 C protease to tumors, resulting in significant tumor growth inhibition and prolonged survival in various solid tumor models.
The researchers identified heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) as the main target degraded by the 3 C protease, highlighting the potential mechanism of action.
The study demonstrates the efficacy of viral protease mRNA in suppressing tumors in multiple cancer types, including glioblastoma, breast cancer, and hepatocellular carcinoma.
The researchers propose that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic due to its ability to target multiple cancer types.
The study suggests that further investigation is needed to explore the potential of viral protease mRNA for cancer gene therapy.

Statistics:

The study demonstrated a significant inhibition of tumor growth (p < 0.01) in glioblastoma models after intracranial injection of LNPs carrying mRNA encoding the 3 C protease.
The researchers observed a 50% reduction in tumor volume (p < 0.05) in breast cancer models after subcutaneous injection of LNPs.
The study showed a 30% inhibition of angiogenesis (p < 0.01) in hepatocellular carcinoma models after intravenous injection of LNPs.

Sources:

Yang, X., et al. (Nature Communications, 2025,16(1):1-15, https://www.nature.com/ncomms/)
NewsRx. (Angiogenesis Weekly, May 30, 2025; p 5, https://newsrx.com/)